
Inside the Hidden World of Phase 1 Drug Testing
AJMC interviews Jill A. Fisher, PhD, author of a new book, Adverse Events: Race, Inequality, and the Testing of New Pharmaceuticals. Her research took her inside clinical testing sites for phase 1 drug studies.
In the world of drug development, it is typically the outcomes of phase 3 clinical trials that get the most attention. With the possibility of game-changing treatments for a myriad of diseases, they garner the most headlines, especially as the world waits on vaccines and effective treatment for the coronavirus disease 2019 pandemic.
But what happens during the early phase of testing? On today’s episode of Managed Care Cast, we speak with Jill A. Fisher, PhD, author of a new book,
Listen above or through one of these podcast services:
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.